Laura Bessen
Patrimonio netto: - $ in data 30/06/2026
Patrimonio netto: - $ in data 30/06/2026
Laura Bessen is currently an Independent Director at C4 Therapeutics, Inc. since 2022.
Formerly, Dr. Bessen was an Independent Director at Artiva Biotherapeutics, Inc. from 2022 to 2025 and served as Vice President & Head-US Medical at Bristol Myers Squibb Co. from 2001 to 2016.
Education includes undergraduate studies at the State University of New York at Binghamton and a doctorate from New York University School of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 24/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| C4 THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/08/2022 |
| Società | Posizione | Fine |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Direttore/Membro del Consiglio | 24/06/2025 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2016 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
State University of New York at Binghamton
State University of New York at Binghamton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale